Business · 10/01/2025Updated: 10/17/2026 · 1 min read
FDA Awards Priority Review Voucher to Neurocrine Biosciences for Rare Pediatric Disease Product CRENESSITY
Summary
The FDA has awarded a priority review voucher to Neurocrine Biosciences, Inc. for its rare pediatric disease product CRENESSITY (crinecerfont), approved on December 13, 2024.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →